C12N2506/025

METHOD OF OBTAINING HSC POPULATION, T CELL POPULATION AND NK CELL POPULATION AND COMPOSITIONS THEREOF
20240287458 · 2024-08-29 ·

The present disclosure discloses pharmaceutical compositions comprising hematopoietic stem cells (HSC) cells, NK cells, and T cells individually, having positive and negative surface markers and pharmaceutically acceptable excipients. The present disclosure further relates to the method for preparing the composition thereof. The present disclosure also provides a method of treating a subject comprising the use of any of said compositions in treating diseases selected from the group consisting of graft versus host disease, malignant disease, and non-malignant disease.

Perinatal tissue derived mesenchymal stem cells: method of preparation and uses thereof

The present invention discloses the preparation of placenta tissue derived CD106.sup.high CD151+Nestin+ mesenchymal stem cells (MSCs). In a first aspect, the invention relates to a particular method to prepare these cells at industrial scale and the cell population generated thereby. In a second aspect, the invention relates to a cell culture obtained by said particular method, containing placental CD106.sup.high CD151+Nestin+ MSCs expressing the vascular cell adhesion molecule 1 (VCAM-1) marker. The present application shows that said placental CD106.sup.high CD151+Nestin+ MSCs are capable of inducing angiogenesis in vitro and in vivo. The herein presented results also show that administering said placental CD106.sup.high CD151+Nestin+ MSCs to individuals suffering from an ischemic disease or from a disorder of the circulatory system results in a detectable improvement of one or more symptoms of said disease or disorder. Therefore, in a third aspect, the invention relates to placental CD 106.sup.high CD151+Nestin+ MSCs for use as a medicament for treating subjects suffering from an ischemic disease, a disorder of the circulatory system, an immune disease, an organ injury or an organ function failure.

Method of isolating cells for therapy and prophylaxis

Disclosed are methods for isolating endothelial progenitor cells (EPC). More particularly, the present invention discloses methods for isolating endothelial progenitor cells that exhibit self-renewal and differentiation capacity. The isolated cellular population of the present invention is useful in a wide range of clinical and research setting including inter alia, the in vitro or in vivo generation of endothelial cells and the therapeutic or prophylactic treatment of a range of conditions via the administration of these cells. Also facilitated is the isolation of endothelial progenitor cells for research purposes such as in vitro based screening systems for testing the therapeutic impact and/or toxicity of potential treatment or culture regimes to which these cells may be exposed to. The present invention also discloses methods for isolating mesenchymal stem cells, in particular mesenchymal stem cells of fetal and/or maternal origin. These cells are also useful in a range of in vitro and in vivo therapeutic, prophylactic and research applications.

Method for preparing induced pluripotency stem cells from mesenchymal stem cells by using phlorotannin fraction
10131881 · 2018-11-20 · ·

The present invention relates to a medium composition for the dedifferentiation of induced pluripotency stem cells, containing a phlorotannin fraction extracted and isolated from one type of brown algae selected from the group consisting of Ecklonia cava, Dictyopteris prolifera, Dictyota coriacea, Sargassum horneri, Ishige okamurai and the like. In addition, the present invention relates to a method for preparing induced pluripotency stem cells by using the medium composition. Induced pluripotency stem cells can be safely, easily and effectively prepared by using mesenchymal stem cells by using the medium composition of the present invention, and the prepared induced pluripotency stem cells can be differentiated into various cells, and thus can be useful as a cell therapeutic agent.

ENHANCED POSTNATAL ADHERENT CELL, AND USE FOR SAME
20180325960 · 2018-11-15 · ·

The present invention relates to an enhanced postnatal adherent cell (ePAC), a method for producing same, and a composition and a cell therapeutic agent having same as an active ingredient.

METHODS FOR DIRECTED DIFFERENTIATION OF PLURIPOTENT STEM CELLS TO IMMUNE CELLS

Provided herein are methods for the efficient in vitro differentiation of somatic cell-derived pluripotent stem cells to hematopoietic precursor cells, and the further differentiation of the hematopoietic precursor cells into immune cells of various myeloid or lymphoid lineages, particularly T cells, NK cells, and dendritic cells. The pluripotent cells may be maintained and differentiated under defined conditions; thus, the use of mouse feeder cells or serum is not required in certain embodiments for the differentiation of the hematopoietic precursor cells.

Methods and compositions for treatment of bone defects with placental cell populations

Provided herein are methods of using adherent placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. Also provided herein are methods of differentiating the placental stem cells. Further provided herein are methods of using the placental stem cells to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with stem cells and compositions comprising stem cells.

Production of virus-receptive pluripotent stem cell (PSC)-derived hepatocytes

The present disclosure provides methods for maturing hepatocytes comprising culturing with cyclic adenosine monophosphate and a Janus kinase inhibitor. There is also provided a method for screening inhibitors of hepatitis B virus infection and/or replication.

Precursory regulatory cytotrophoblast cells and uses thereof

Disclosed herein are precursory regulatory cytotrophoblast cells produced in vitro and compositions thereof. Disclosed herein are isolated populations of precursory regulatory cytotrophoblast cells, where the cells are produced in vitro. Disclosed herein are genetically engineered cells. Also disclosed herein are methods of treating a disorder or condition by utilizing the cells disclosed herein.

MicroRNAs for the generation of astrocytes

A method of generating a population of cells useful for treating a nerve disease or disorder in a subject, the method comprising up-regulating a level of at least one exogenous miRNA in mesenchymal stem cells (MSCs) and/or down-regulating a level of at least one miRNA using a polynucleotide agent that hybridizes to the miRNA, thereby generating the population of cells useful for treating the nerve disease or disorder. Isolated populations of cells with an astrocytic phenotype generated thereby and uses thereof are also provided.